Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs iShares Core S&P 500 ETF (IVV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs iShares Core S&P 500 ETF — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.69 (market cap $6.04B), while iShares Core S&P 500 ETF trades at $782.5 (market cap $897.20B). The key difference: iShares Core S&P 500 ETF is far larger — about 148.5× Iovance Biotherapeutics Inc. Common Stock's market cap, and Iovance Biotherapeutics Inc. Common Stock is more actively traded (14,805,993 versus 4,580,672). Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and iShares Core S&P 500 ETF for 46 Days on average.
| IOVA | IVV | |
|---|---|---|
Market Cap | $6.04B | $897.20B |
Volume | 14,805,993 | 4,580,672 |
Sector | Health | Broad Market / Factor |
52-Week High | $14.82 | $782.58 |
52-Week Low | $1.81 | $634.93 |
Typical Hold Time | 0 Days | 46 Days |
Enterprise Value | $5.97B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IVV, tracking the S&P 500, trades at $782.06, up 0.19% with a bullish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at 68.88 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation debates, with earnings growth expected to slow from 35% in 2026 to 15% in 2027 according to Wall Street analysts (24/7 Wall Street, 2026-10-03).
The outlook remains cautiously optimistic with seasonal patterns favoring year-end rallies, though concentration risks in top holdings and slowing profit growth present headwinds. Key support at $775 and resistance at $780 will dictate near-term direction as investors monitor economic data and Federal Reserve policy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About iShares Core S&P 500 ETF
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →
